Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 2, 2010, Pages 83-93

  Arnold, L Eugene ^a,b   Farmer, Cristan ^b   Kraemer, Helena Chmura ^c,d   Davies, Mark ^e   Witwer, Andrea ^b   Chuang, Shirley ^f   Disilvestro, Robert ^e   McDougle, Christopher J ^g   McCracken, James ^g   Vitiello, Benedetto ^h   Aman, Michael G ^b   Scahill, Lawrence ⁱ   Posey, David J ^e   Swiezy, Naomi B ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e INDIANA UNIVERSITY   (United States)

^f University of California Semel Institute ^*

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE; ZINC;

ADOLESCENT; ARTICLE; AUTISM; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; WEIGHT GAIN;

ADOLESCENT; AUTISTIC DISORDER; BIOMARKERS, PHARMACOLOGICAL; CHILD; CHILD, PRESCHOOL; CONTROLLED CLINICAL TRIALS AS TOPIC; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IRRITABLE MOOD; MALE; MEDICATION ADHERENCE; RISPERIDONE;

EID: 77951668684     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0022     Document Type: Article

References (25)

1. Allison D, Mentore J, Heo M, Chandler L, Cappelleri J, Infante M, Weiden P: Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696, 1999.
2. Aman MG, Singh NN, Stewart AQ, Field CJ: The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-491, 1985.
3. th ed. (DSM-IV). Washington (DC): American Psychiatric Association, 1994.
4. Arnold LE, Aman MG, Martin A, Collier-Crespin A, Vitiello B, Tierney E, Asarnow R, Bell-Bradshaw F, Freeman BJ, Gates-Ulanet P, Klin A, McCracken JT, McDougle CJ, McGough JJ, Posey DJ, Scahill L, Swiezy NB, Ritz L, Volkmar F: Assessment in multisite randomized clinical trials (RCTs) of patients with autistic disorder: The Autism RUPP network. J Autism Dev Disord 30:99-111, 2000.
5. Bales C, DiSilvestro R, Currie K, Plaisted C, Joung H, Galanos A, Lin P: Marginal zinc deficiency in older adults: Responsiveness of zinc status indicators. J Am Coll Nutr 13:455-462, 1994.
6. Baron R, Kenny D: The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51:1173-1182, 1986.
7. Belfield A, Goldberg DM: Normal ranges and diagnostic value of serum 5-nucleotidase and alkaline phosphatase activities in infancy. Arch Dis Child 46:842-846, 1971.
8. Blostein-Fujii A, DiSilvestro RA, Frid D, Katz C, Malarkey W: Short term zinc supplementation in type II diabetic women: Effects on plasma 5-nucleotidase activities, insulin-like growth factor levels & lipoprotein oxidation rates in vitro. Am J Clin Nutr 66:639-642, 1997.
9. Chauhan A, Chauhan V, Brown W, Cohen I: Oxidative stress in autism: Increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin\the antioxidant proteins. Life Sci 75:2539-2549, 2004.
10. DiSilvestro RA: Plasma levels of immunoreactive ceruloplasmin and other acute phase proteins during lactation. Proc Soc Exp Biol Med 183:257-261, 1986.
11. Faber S, Zinn G, Kern J, Kingston H: The plasma zinc=serum copper ratio as biomarker in children with autism spectrum disorders. Biomarkers 14(3): 171-180, 2009.
12. Holmbeck G: Toward terminological, conceptual, and statistical clarity in the study of mediators and moderators: Examples from the child-clinical and pediatric psychology literatures. J Consult Clin Psych 65:599-610, 1997.
13. Klein D, Cottingham E, Sorter M, Barton B, Morrison J: A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 163:2072-2079, 2006.
14. Kraemer H, Blasey C: Centring in regression analyses: A strategy to prevent errors in statistical inference. Int J Methods Psychiatr Res 13:141-151, 2004.
15. Kraemer H, Wilson G, Fairburn C, Agras W: Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 59:877-883, 2002.
16. Kraemer H, Kiernan M, Essex M, Kupfer D: How and why criteria defining moderators and mediators differ between the Baron & Kenny and MacArthur approaches. Health Psychol 27:S101-S108, 2008.
17. Lord C, Rutter M, LeCouteur A: Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659-685, 1994.
18. McCracken J, Aman M, McDougle C, Scahill L, Tierney E, Arnold L, Posey D, Whelan F, Chuang S, Ritz L, Vitiello B, Research Units on Pediatric Psychopharmacology Autism Network: Dopamine genes and weight in children with autism treated with risperidone. Submitted for publication.
19. McDougle C, Scahill L, McCracken J, Aman M, Tierney E, Arnold L, Freeman B, Martin A, McGough J, Cronin P, Posey D, Riddle M, Ritz L, Swiezy N, Vitiello B, Volkmar F, Votolato N, Walson P: Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 9:201-224, 2000.
20. Prasad AS, The Biochemistry of Zinc. Norwell (Massachusetts): Kluwer Academic Publishers, 1994.
21. RUPP (Research Units on Pediatric Psychopharmacology) Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321, 2002.
22. Sahakian BJ, Robbins TW: Are the effects of psychomotor stimulant drugs on hyperactive children really paradoxical? Med Hypotheses 3:154-158, 1977.
23. Scahill L, Riddle M, McSwiggin-Hardin M, Ort S, King R, Goodman W, Cicchetti D, Leckman J: Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity. J Am Acad Child Adolesc Psychiatry 36:844-852, 1997.
24. Scahill L, McCracken J, McDougle C, Aman M, Arnold LE, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey D, Swiezy N, Volkmar F, Ritz L, Vitiello B. Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. J Child Ado-lesc Psychopharm 11:377-388, 2001.
25. Wu R, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: A randomized controlled trial. J Am Med Assoc 299:185-193, 2008.